Federated Hermes, Inc. Aerie Pharmaceuticals Inc Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$6.37 - $15.23 $5,108 - $12,214	802 New	802 $12,000
Q3 2018 Nov 13, 2018	SELL	$56.15 - $73.9 $704,514 - $927,223	-12,547 Reduced 99.82%	22 $1,000
Q2 2018 Aug 10, 2018	BUY	$47.85 - $70.45 $601,426 - $885,486	12,569 New	12,569 $849,000
Q1 2018 May 09, 2018	SELL	$51.15 - $61.0 $487,817 - $581,757	-9,537 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$50.85 - $65.1 $196,230 - $251,220	3,859 Added 67.96%	9,537 $0
Q3 2017 Nov 13, 2017	BUY	$48.6 - $60.1 $275,950 - $341,247	5,678	5,678 $276,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.